|Day Low/High||49.37 / 49.93|
|52 Wk Low/High||37.62 / 51.84|
These firms offer strong dividends, cash flow and trailing 12-month sales.
An inverse head and shoulders pattern could soon develop.
Syringe-seller Unilife is gaining momentum - and scaring the shorts - after signing a big deal with Sanofi, says Alan Shortall, CEO of Unilife.
Gladstone Land, KaloBios Pharmaceuticals and Stemline Therapeutics plan to go public, IPO Desktop President Francis Gaskins isn't sure the risk is worth it.
Jeanie Wyatt, CEO of South Texas Money Management, names her favorite stocks including Wells Fargo and Sanofi.
These drug companies addressing prostate cancer get high grades from my guru strategies.
This drugmaker has fallen from a nine-month high to a key support level in just five sessions.
Forest Labs has potential volatility and high short interest, and Sanofi has crossed some key levels.
Stephanie Link, director of research for TheStreet, explains why Sanofi is an attractive investment under $35.
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Sanofi-Aventis, Cypress Semiconductor and Biogen.
In the large, but targeted, market for diabetes drugs, two very different companies share a deeper commitment.
European headlines worried traders ahead of the open, as they await a raft of economic and retail reports.
If you need to live on investment income, bonds and CDs are not enough -- you need dividends.
Set your portfolio up with both long and short exposure in case of a series of bank failures.